Tag - XCUR

Developments

Exicure doses first patient in Phase 2 portion of Merkel cell carcinoma trial

Exicure (NASDAQ:XCUR) dosed the first patient in the Phase 2 dose expansion portion of a clinical trial evaluating cavrotolimod for the treatment of Merkel cell carcinoma. The Phase 2 portion of the ongoing Phase 1b/2...

June 16, 2020

Markets

Exicure to uplist to NASDAQ; prices $55-million public offering

Exicure’s (OTCQB:XCUR) common stock will begin trading on the Nasdaq Capital Market under the symbol “XCUR” at the opening of trading on July 31, 2019. Exicure also priced its public offering of 27,500,000 shares of its...

July 31, 2019

Feature

Exicure readies two clinical data readouts later this quarter

By Len Zehrs Exicure (OTCQB:XCUR) expects to report data around the end of the third quarter of 2018 from two Phase 1 clinical trials, one in mild-to-moderate psoriasis and one in healthy volunteers with its lead...

August 7, 2018

Tag - XCUR

Exicure doses first patient in Phase 2 portion of Merkel cell carcinoma trial

Exicure to uplist to NASDAQ; prices $55-million public offering

Exicure readies two clinical data readouts later this quarter

General

More